Emmaus Life Sciences Files 8-K on Financials
Ticker: EMMA · Form: 8-K · Filed: Jul 3, 2024 · CIK: 822370
| Field | Detail |
|---|---|
| Company | Emmaus Life Sciences, INC. (EMMA) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
Emmaus Life Sciences dropped an 8-K on July 3rd detailing financials and past name changes.
AI Summary
Emmaus Life Sciences, Inc. filed an 8-K on July 3, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company was formerly known as MYnd Analytics, Inc., CNS RESPONSE, INC., and STRATIVATION, INC., with name changes occurring on December 11, 2015, March 13, 2007, and November 15, 2005, respectively.
Why It Matters
This 8-K filing provides an update on Emmaus Life Sciences' financial condition and operations, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate material adverse events.
Key Players & Entities
- Emmaus Life Sciences, Inc. (company) — Registrant
- July 3, 2024 (date) — Date of earliest event reported
- MYnd Analytics, Inc. (company) — Former company name
- CNS RESPONSE, INC. (company) — Former company name
- STRATIVATION, INC. (company) — Former company name
- 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 (address) — Company business and mail address
FAQ
What is the primary purpose of this 8-K filing for Emmaus Life Sciences, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on July 3, 2024.
What were some of the previous names of Emmaus Life Sciences, Inc.?
Emmaus Life Sciences, Inc. was formerly known as MYnd Analytics, Inc., CNS RESPONSE, INC., and STRATIVATION, INC.
On what dates did the company's name changes occur?
The name changes occurred on December 11, 2015 (MYnd Analytics, Inc.), March 13, 2007 (CNS RESPONSE, INC.), and November 15, 2005 (STRATIVATION, INC.).
What is the business address of Emmaus Life Sciences, Inc.?
The business address is 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-07-03 09:40:50
Filing Documents
- ea0207151-8k_emmaus.htm (8-K) — 27KB
- ea020715101ex99-1_emmaus.htm (EX-99.1) — 40KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-058821.txt ( ) — 244KB
- emma-20240703.xsd (EX-101.SCH) — 3KB
- emma-20240703_lab.xml (EX-101.LAB) — 33KB
- emma-20240703_pre.xml (EX-101.PRE) — 22KB
- ea0207151-8k_emmaus_htm.xml (XML) — 3KB
02 Results of Operation and Financial Condition
Item 2.02 Results of Operation and Financial Condition. On July 3, 2024, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") issued a press release announcing the results of operations and financial condition as of and for the year ended December 31, 2023, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which information is incorporated herein by reference. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 3, 2024 Emmaus Life Sciences, Inc. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2 INDEX TO EXHIBITS Exhibit Number Description 99.1 July 3, 2024 Press Release 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3